NCT04999761 2024-09-25AB122 Platform StudyTaiho Pharmaceutical Co., Ltd.Phase 1 Recruiting917 enrolled
NCT02572687 2021-01-20A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesEli Lilly and CompanyPhase 1 Completed85 enrolled